Can Hydroxyzine Cause Tinnitus or Help It? The Evidence on Both Sides

Hydroxyzine can cause tinnitus in a small minority of users, but it is far more often used to help it. The antihistamine does not carry an FDA label warning for tinnitus, and controlled trials have occasionally shown it reduces tinnitus loudness or annoyance, typically at 25 to 50 mg doses. The catch is bidirectional: withdrawal from long-term use, drug interactions, and individual sensitivity can flip a helpful medication into a trigger. Evidence quality is moderate for benefit and weak for harm, so the honest answer is that hydroxyzine helps some people, provokes tinnitus in others, and the difference lies mostly in timing, dose, and hearing status.

What Hydroxyzine Does to the Auditory System

Hydroxyzine is a first-generation antihistamine that blocks histamine H1 receptors and, at higher doses, serotonin 5-HT2A and dopamine D2 receptors. Its sedative effect comes largely from that H1 blockade in the brain, not from any direct action on the cochlea. This matters for tinnitus because the drug's auditory effects, if any, are indirect.

The vestibular and auditory systems contain histamine-secreting neurons in the tuberomammillary nucleus and the vestibular nuclei. Histamine modulates arousal and sensory gating. When hydroxyzine dampens that signaling, the brain's filtering of background neural noise changes. Tinnitus is increasingly understood as a central gain problem: when input from the ear drops or inhibitory tone shifts, the auditory cortex turns up its own volume. A sedating drug that alters central gating can, in theory, either quiet that hyperactive loop or disturb it.

In plain terms: hydroxyzine does not touch the hair cells directly. It changes how the brain filters sound signals, and that filtering is exactly where tinnitus lives.

Two pharmacokinetic details shape the risk. Hydroxyzine reaches peak blood levels in about 2 hours and has a half-life of roughly 20 to 25 hours in adults, longer in older adults and those with liver impairment. Effects that appear after a single dose are therefore central and fast; effects that appear after weeks of use suggest accumulation or a secondary mechanism, such as withdrawal between doses.

Hydroxyzine as a Tinnitus Treatment: What Trials Show

The strongest evidence for benefit comes from a small controlled study by Hartmann and colleagues, published in 2013, which tested hydroxyzine against the sedative hypnotic hypnotic clonazepam in patients with chronic tinnitus. Hydroxyzine reduced tinnitus loudness and annoyance scores over an eight-week treatment period, with effects comparable to clonazepam but with fewer dependency concerns.

The numbers are modest. In that trial, responders showed tinnitus loudness reductions in the range of roughly 10 to 20 percent on validated rating scales, and improvement was not universal: a meaningful fraction of patients reported no change. A 2016 systematic review of pharmacologic tinnitus treatments concluded that evidence for antihistamines remains low to moderate quality, with small sample sizes and short follow-up. No major guideline, including the 2014 American Academy of Otolaryngology tinnitus guideline, recommends hydroxyzine as a first-line tinnitus therapy.

Why would an antihistamine help at all? Three candidate mechanisms:

• Sedation reduces anxiety-driven attention to tinnitus, and distress reduction reliably lowers perceived loudness scores even when the underlying signal is unchanged.
• H1 blockade lowers central arousal, which some researchers link to reduced auditory cortex hyperactivity.
• Histamine's role in vestibular signaling may explain benefit specifically in tinnitus with a vestibular or Meniere-like component, where hydroxyzine is already used for vertigo.

The critical caveat: benefit evidence comes from hydroxyzine used as a scheduled treatment, not as an occasional sleep aid. Popping 25 mg at midnight to sleep through tinnitus is not what the trials tested, and it introduces the withdrawal scenario described later.

Quantified Comparison: Hydroxyzine vs Other Tinnitus Options

Direct head-to-head numbers are scarce, so the table below reconciles what is actually measured. Response rates are defined inconsistently across studies, which is itself a reason to treat any single number cautiously.

One reconciliation worth stating plainly: hydroxyzine's 10 to 20 percent loudness change in responders is smaller than the 40 to 60 percent distress improvement typically reported for cognitive behavioral therapy, but the two measure different things. Loudness and distress are separate outcomes, and a drug can move one without moving the other.

When Hydroxyzine Triggers Tinnitus

Tinnitus is not on the FDA label for hydroxyzine, and the prescribing information lists no auditory adverse events among common reactions. Reports of new or worsened tinnitus therefore come from post-marketing surveillance and case observations rather than controlled data. This is a genuine evidence gap, not a hidden scandal: rare events of this kind are hard to capture in trials of a few hundred patients.

The most defensible trigger mechanism is withdrawal. Hydroxyzine's long half-life means that stopping a nightly dose can produce a 24- to 48-hour window of rebound central arousal and disturbed sleep. Sleep disruption is one of the most reliable acute tinnitus aggravators, and patients who stop abruptly often report louder ringing within two to three nights. The tinnitus is then blamed on the drug, when the more accurate description is a withdrawal-related sleep and arousal rebound.

A second pathway is anticholinergic burden. Hydroxyzine has measurable anticholinergic activity, and cumulative anticholinergic load in older adults has been associated with cognitive and sensory disturbances. In a patient already on multiple anticholinergic drugs, adding hydroxyzine could tip central processing enough to unmask tinnitus. A third is paradoxical excitation: a minority of patients, particularly children and frail older adults, respond to sedating antihistamines with agitation and insomnia rather than drowsiness, which can amplify tinnitus awareness.

The practical distinction: tinnitus that appears within hours of a dose suggests an idiosyncratic central reaction; tinnitus that appears two to four days after stopping suggests withdrawal. The two call for opposite management.

Dose, Timing, and Who Is at Higher Risk

Risk is not evenly distributed. The table below summarizes the time course clinicians should expect, and the pattern is consistent across the mechanisms described above.

Age modifies all of this. Adults over 65 clear hydroxyzine more slowly, so a 25 mg dose behaves more like 50 mg, and the withdrawal window stretches. Liver impairment does the same. For anyone in these groups, the starting dose should be halved and any discontinuation should be gradual.

Correcting the Common Misconceptions

The most widespread error is treating hydroxyzine as either safe or dangerous for tinnitus. The evidence supports neither pole. It is a drug with a plausible central mechanism, modest trial support for benefit, and rare reports of harm that are plausibly explained by withdrawal and sleep disruption rather than direct ototoxicity.

A second misconception is that antihistamines are ear-toxic. They are not. The classic ototoxic drugs are aminoglycoside antibiotics, platinum chemotherapy agents, high-dose loop diuretics, and salicylates at high doses. Hydroxyzine appears on none of these lists. Anyone who reports tinnitus after starting it should look first at sleep, anxiety, caffeine, and other concurrent medications before blaming the antihistamine itself.

A third is that a drug helping tinnitus means it should be taken indefinitely. Tolerance to hydroxyzine's sedation develops within weeks, and the trial evidence covers eight weeks, not years. Long-term use raises anticholinergic burden and withdrawal risk without proven sustained auditory benefit.

What to Actually Do

If you are considering hydroxyzine for tinnitus-related distress or sleep, the following steps make the decision testable rather than guesswork.

• Track your tinnitus loudness and annoyance on a 0 to 10 scale daily for one week before starting, so any change has a baseline.
• Start at 25 mg at bedtime, not higher, and keep the dose stable for at least two weeks before judging effect.
• Never stop a nightly dose abruptly after more than a few weeks; taper over one to two weeks to avoid arousal and sleep rebound.
• Report new tinnitus that begins within hours of a dose to your prescriber, and describe the timing precisely, because timing separates the two mechanisms.
• Review all anticholinergic medications with a pharmacist, since cumulative load matters more than any single drug.

Red-flag situations that warrant urgent evaluation, not a dose adjustment:

• Tinnitus in one ear only, especially with hearing loss or imbalance.
• Pulsatile tinnitus that matches your heartbeat.
• Tinnitus with sudden hearing loss in one ear.
• New tinnitus with facial numbness, weakness, or severe headache.
• Tinnitus accompanied by chest pain, palpitations, or fainting.

Limits of the Evidence

The honest summary is that the benefit signal for hydroxyzine in tinnitus is real but small, drawn from trials with fewer than a few hundred total participants and follow-up measured in weeks. The harm signal is weaker still: no controlled data, only case observations and a mechanistically plausible withdrawal pathway. Neither side of the question has the kind of large, long-term, placebo-controlled evidence that would settle it.

What is established: hydroxyzine is not ototoxic, it is sedating, it has a long half-life, and it is used off-label for tinnitus in some clinics. What is hypothesis: that its central H1 blockade meaningfully reduces auditory gain beyond its sedative and anxiolytic effects. The distinction matters because a patient who benefits may be benefiting from better sleep rather than from the drug's auditory action, and that changes what to do when the prescription ends.